Programs and studies

Clinical study

Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia

StatusNot yet recruiting
TypeTrial
CountriesLocation not listed
Conditions studiedVAP - Ventilator Associated Pneumonia
Study years2025 (estimated)–2028 (estimated)
Entry review2026-10-03

Participation

Check the study record or contact the study team for current recruitment and eligibility.

Study eligibility

Inclusion Criteria: 1. Diagnosed with ventilator-associated pneumonia (VAP); 2. Identified infection with MDR Klebsiella pneumoniae, Acinetobacter baumannii, or Pseudomonas aeruginosa via MROSE evaluation and antimicrobial susceptibility testing (AST) from this or other tertiary hospitals; 3. Aged 18 to 85 years; 4. Written informed consent obtained from the patient or legal guardian. Exclusion Criteria: 1. Pregnant or breastfeeding women; 2. FiO₂ ≥ 70% or PEEP ≥ 15 cmH₂O; 3. Hemodynamic instability (vasopressor dose increased by ≥30% in the last 6 hours or norepinephrine \> 0.5 μg/kg/min); 4. Known allergy to phage components.

Study description

The purpose of this study is to systematically evaluate the efficacy and safety of bacteriophage cocktail therapy in patients with ventilator-associated pneumonia caused by Gram-negative bacterial infections.

Study registrations

ClinicalTrials.govNCT07202234
Sources and updates

Entry reviewed . This is the date of our source review, not a confirmation of availability today.

AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.

Study ID
nct07202234